1. Introduction
Antibody-drug conjugates (ADC) are composed of three main components: the antibody, the drug (often referred to as the payload or a small-molecule toxin), and the linker. ADCs work by using the antibody's specific affinity for a target antigen to deliver the ADC to the target site. Upon binding to the antigen, the ADC is internalized by the target cell, where the payload is then released to exert its cytotoxic effects, eliminating the targeted cell.
Prisys Biotech specializes in preclinical pharmacology research with Cynomolgus macaques, offering comprehensive large-animal studies that provide critical insights into drug behavior and efficacy. Leveraging advanced technology and expertise in ADC pharmacokinetics (PK) and pharmacodynamics (PD), Prisys Biotech supports the drug development process by enabling precise assessment of drug distribution, metabolism, and elimination, helping accelerate the transition from preclinical findings to clinical success.
Since ADC drugs differ from monoclonal antibodies (mAbs) and are generally administered intravenously (IV), this document does not discuss absorption characteristics and instead focuses on the distribution and elimination of ADCs.
2. Distribution of ADC Drugs
As ADCs primarily consist of an antibody structure, their distribution characteristics largely resemble those of naked antibodies. Three main factors influence ADC distribution: target-mediated specific distribution, convective fluid flow between plasma, tissue fluid, and lymph, and the intrinsic properties of the ADC itself.
Target-Mediated Distribution: This process is mainly influenced by the expression of target antigens and the rate of endocytosis. Ideally, the target antigen expression should significantly differ between tumor and normal tissues to enhance therapeutic efficacy and minimize toxicity.
Convective Fluid Flow: Due to their large molecular weight (~150 kDa), ADCs remain in the vasculature shortly after administration, reaching a steady-state volume of distribution (Vss) around 0.2 L/kg.
Intrinsic Properties of the ADC: Molecular size, charge, and hydrophobicity all impact the ADC's ability to traverse capillary pores. High DAR (drug-to-antibody ratio) values, typically above 4, may increase plasma clearance rates and hepatic distribution.
3. Elimination of ADC Drugs
ADC elimination is complex, given its structural composition of antibody, linker, and payload. Key mechanisms include:
3.1 Target-Mediated Elimination: Following binding with membrane surface antigens, ADCs undergo receptor-mediated endocytosis and lysosomal degradation. Higher endocytic rates facilitate drug efficacy by enabling ADC internalization and payload release.
3.2 FcRn Receptor Interaction: The FcRn receptor protects the ADC from degradation within cells, extending plasma half-life and potentially enhancing ADC-mediated antibody-dependent cellular cytotoxicity (ADCC) effects.
3.3 Linker Stability: Linkers are classified as cleavable or non-cleavable, impacting payload release mechanisms and influencing both efficacy and toxicity. Cleavable linkers rely on pH differences or specific enzymes, while non-cleavable linkers release payloads only upon antibody breakdown.
3.4 Payload Dynamics: Once released, payloads may either diffuse freely or remain localized. Payloads that are substrates of efflux transporters, such as P-glycoprotein, may require modifications to increase retention within target cells.
4. Conclusion
This article has outlined the ADME mechanisms and influencing factors for ADC drugs, acknowledging that further research is needed to fully understand these mechanisms due to the relative novelty of ADC drugs in comparison to small-molecule drugs.
With cutting-edge facilities and a team experienced in large-animal pharmacology, Prisys Biotech remains at the forefront of preclinical research services. Our PK and PD studies, particularly with non-human primates, offer an invaluable platform for advancing ADC and other biologic drugs. We invite you to learn more about our capabilities and how we can contribute to your drug development programs with reliable, data-driven insights.
